Regarding the site of initial postoperative recurrence in patients who were pTanypN0 M0 at the time of nephroureterectomy, patients with postoperative lymph node recurrence had a worse prognosis than those with bladder recurrence, probably because many bladder cancers were detected at the superficial stage by active surveillance.
Out of 4310 individuals who were administered dapagliflozin, nine total cases of bladder cancer were detected, while one of 1962 subjects had bladder cancer in the control group.
High expression of Ras protein and RbAp46 protein and low expression of RECK protein were detected in bladder cancer specimens.
The expressions of netrin-1/UNC5B were detected in bladder cancer tissues & adjacent tissues and the relevance and the relationship with clinic pathological parameters was analyzed.
Alterations of several proteins of the ET axis were detected in invasive bladder cancer.
Overexpression of wild-type Aurora-A and mutation of RasV12 were detected in human bladder and colon cancer tissues.
In fact, higher relative levels (>10 fold) of TAp73 mRNA were found in spleen, fat, kidney and bladder, while intermediate levels (<10 fold) were detected in liver, lung and gut.
Both were detected in adult spleen, bladder, intestine, lung, kidney and teeth, and in lung and skin of newborn mice.
However, in patients receiving pioglitazone for ≥24 months, there was slight increased bladder cancer risk (1.4 [1.03–2.0]); 95% of cancers were detected at an early in situ stage, and authors acknowledged that this could have been attributed to the fact that pioglitazone-treated patients underwent greater surveillance for bladder cancer.
